Clinical Trial

Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors

Name: Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors — clinical trial record (NCT05768464)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: IUNU-RC

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The goal of this prospective, multicenter, single-arm clinical study is to evaluate the efficacy and safety of toripalimab in combination with axitinib for postoperative adjuvant therapy for non-clear renal cell carcinoma with high-risk recurrence factors.

Trial Details

NCT Number	NCT05768464
Lead Sponsor	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions	Non-clear Renal Cell Carcinoma
Enrollment	30 participants
Start Date	2023-02-01
Primary Completion	2026-12-30 (estimated)
Study Completion	2027-12-30 (estimated)
Updated on ClinicalTrials.gov	2023-03-14